|
1
|
Catovsky D, Fooks J and Richards S:
Prognostic factors in chronic lymphocytic leukaemia: the importance
of age, sex and response to treatment in survival. A report from
the MRC CLL 1 trial MRC Working Party on Leukaemia in Adults. Br J
Haematol. 72:141–149. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reed JC: Molecular biology of chronic
lymphocytic leukemia: implications for therapy. Semin Hematol.
35:3–13. 1998.PubMed/NCBI
|
|
3
|
Jewell AP: Role of apoptosis in the
pathogenesis of B-cell chronic lymphocytic leukaemia. Br J Biomed
Sci. 59:235–238. 2002.PubMed/NCBI
|
|
4
|
Rassenti LZ, Jain S, Keating MJ, et al:
Relative value of ZAP-70, CD38, and immunoglobulin mutation status
in predicting aggressive disease in chronic lymphocytic leukemia.
Blood. 112:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inoue S, Riley J, Gant TW, Dyer MJ and
Cohen GM: Apoptosis induced by histone deacetylase inhibitors in
leukemic cells is mediated by Bim and Noxa. Leukemia. 21:1773–1782.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogler M, Butterworth M, Majid A, et al:
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately
1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Blood. 113:4403–4413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi(m)) in apoptosis; an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kiss T: Apoptosis and its functional
significance in molluscs. Apoptosis. 15:313–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smolewski P, Duechler M, Linke A, et al:
Additive cytotoxic effect of bortezomib in combination with
anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic
leukemia cells. Leuk Res. 30:1521–1529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faderl S, Rai K, Gribben J, et al: Phase
II study of single-agent bortezomib for the treatment of patients
with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cancer. 107:916–924. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu FT, Agrawal SG, Gribben JG, et al:
Bortezomib blocks Bax degradation in malignant B cells during
treatment with TRAIL. Blood. 111:2797–2805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu WX, Zhou M, Cai ZB and Yang YZ:
Synthesis of new type antineoplastic drug
3,6-dimethyl-1,4-dihydro-s-tetrazine-1,4-dicarboamide. Patent,
China. 2004.
|
|
14
|
Rao GW and Hu WX: Synthesis, structure
analysis, and antitumor activity of
3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg
Med Chem Lett. 16:3702–3705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Y, Lv Y, Xu W and Hu W: Determination
of proteasome activities with fluorogenic kinetic assays and its
application in screening proteasome inhibitor. Chi J Clin Phar
Therap. 10:1127–1133. 2008.
|
|
16
|
Horie R, Watanabe T, Morishita Y, et al:
Ligand-independent signaling by overexpressed CD30 drives NF-kappaB
activation in Hodgkin-Reed-Sternberg cells. Oncogene. 21:2493–2503.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin SJ, Reutelingsperger CP, McGahon
AJ, et al: Early redistribution of plasma membrane
phosphatidylserine is a general feature of apoptosis regardless of
the initiating stimulus: inhibition by overexpression of Bcl-2 and
Abl. J Exp Med. 182:1545–1556. 1995. View Article : Google Scholar
|
|
18
|
Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K and
Qin ZH: Blocking NF-kappaB nuclear translocation leads to
p53-related autophagy activation and cell apoptosis. World J
Gastroenterol. 17:478–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petit PX, Susin SA, Zamzami N, Mignotte B
and Kroemer G: Mitochondria and programmed cell death: back to the
future. FEBS Lett. 396:7–13. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shakir FK, Audilet D, Drake AJ III and
Shakir KM: A rapid protein determination by modification of the
Lowry procedure. Anal Biochem. 216:232–233. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cory S and Adams JM: The Bcl2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reed JC: Double identity for proteins of
the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chao DT and Korsmeyer SJ: BCL-2 family:
regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar
|
|
27
|
Reed JC: Bcl-2 family proteins. Oncogene.
17:3225–3236. 1998. View Article : Google Scholar
|
|
28
|
Nicholson DW, Ali A, Thornberry NA, et al:
Identification and inhibition of the ICE/CED-3 protease necessary
for mammalian apoptosis. Nature. 376:37–43. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Almond JB, Snowden RT, Hunter A, Dinsdale
D, Cain K and Cohen GM: Proteasome inhibitor-induced apoptosis of
B-chronic lymphocytic leukaemia cells involves cytochrome c release
and caspase activation, accompanied by formation of an
approximately 700 kDa Apaf-1 containing apoptosome complex.
Leukemia. 15:1388–1397. 2001. View Article : Google Scholar
|
|
30
|
Duechler M, Linke A, Cebula B, et al: In
vitro cytotoxic effect of proteasome inhibitor bortezomib in
combination with purine nucleoside analogues on chronic lymphocytic
leukaemia cells. Eur J Haematol. 74:407–417. 2005. View Article : Google Scholar
|
|
31
|
Smolewski P, Duechler M, Linke A, Cebula
B, Schwarzmeier JD and Robak T: Cytotoxic effect of proteasome
inhibitor bortezomib in combination with ourine nucleoside
analogues on chronic lymphocytic leukemia cells in vitro. Blood.
104:288–294. 2004.
|
|
32
|
Qiu LN, Zhou YL, Qiang H and Hu WX:
Effects of ZGDHu-1 on CD4+CD25+ regulatory T
cells in patients with chronic B cell lymphocytic leukemia in
vitro. Chi J Hematol. 12:841–843. 2010.
|
|
33
|
Cuni S, Perez-Aciego P, Perez-Chacon G, et
al: A sustained activation of PI3K/NF-kappaB pathway is critical
for the survival of chronic lymphocytic leukemia B cells. Leukemia.
18:1391–1400. 2004. View Article : Google Scholar : PubMed/NCBI
|
